Sanofi (SNY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sanofi's Consumer Healthcare Unit Gets OK to Trial Cialis as Over-the-counter Medicine in US
MT Newswires01:41 ET
Opella, Part Of Sanofi, Secures FDA Clearance To Begin Trial For OTC Cialis
Benzinga01:24 ET
Sanofi (SNY.US) "star small molecule" protein degraders new drug has been approved for clinical use in China.
The "Star Small Molecule" protein degrader new drug from Sanofi (SNY.US) has been approved for clinical use in China.
Zhitong Finance01:09 ET
Press Release: Opella Reaches Study Milestone for Cialis
Sanofi00:00 ET
SK Bioscience and Sanofi's GBP410 Vaccine Enters Global Phase III Trials
Yahoo Finance12:59 ET
Sanofi's Growth Prospects and Undervalued Position Highlighted by Analyst Graham Parry
TipRanksJan 20 08:15 ET

Comments

Moomoo Recap US

Dec 17, 2024 15:03

Columns Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today

The market fell Tuesday, but stepping back, the view of tech stocks looks like a mountain range that has not peaked yet- for all of December, the Nasdaq has arched upward into all-time highs. After Monday's record, the index pulled back, following a pullback for Nvidia and Broadcom, falling after Broadcom's post-earnings stock jump finally took a pause.
Just past 4 pm ET they $S&P 500 Index (.SPX.US)$ traded down 0.39%,...

16

3

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

11

2

4

Meltyy

Sep 25, 2024 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

9

1

Meltyy

Sep 10, 2024 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

5

1

Trytosaveabit

Sep 9, 2024 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

1

SNY Sanofi

Trade Overview

Capital Trend

News

Comments